Galenica remains on growth track

Press release
Ad hoc announcement pursuant to Art. 53 LR

• Galenica Group sales grew 4.7% to CHF 2,999.7 million in the third quarter of 2025.
• Sales growth is driven by prescription drugs and dietary supplements.
• Thanks to the acquisition of Labor Team, Galenica now expects sales growth of between 4% and 6% and an increase in EBIT¹ of between 10% and 12%. 

Galenica continued to grow in the third quarter of 2025 and generated sales of CHF 2,999.7 million to the end of September. Both the “Products & Care” segment (+5.0%) and “Logistics & IT” segment (+5.0%) contributed to the 4.7% increase in sales. 

This puts Galenica in line with the growth of the market; over the same period the pharmaceutical market² grew 5.1% and the consumer healthcare market⁵ declined 0.4%.

In the first half of 2025 the Galenica Group achieved an increase in sales of 5.0%. A slight slowdown in growth was seen in the third quarter as expected due to the strong prior-year period. Growth continues to be driven by strong demand for prescription drugs, including GLP-1-based³ weight loss products as well as sales of dietary supplements.

The acquisition of the Labor Team Group, which was completed on 9 September 2025, also contributed to sales growth. Without this acquisition sales would have grown 4.4% to the end of the third quarter of 2025.

Guidance increased due to acquisition of Labor Team

The acquisition of Labor Team will increase the Group’s sales and earnings base. Galenica now expects sales growth of between 4% and 6% and an increase in EBIT¹ of between 10% and 12%. The effects of acquisition-related amortization cannot yet be reliably quantified at this point and are not included in the EBIT¹ guidance mentioned.

Excluding the additional contribution to sales and EBIT¹ from the acquisition of Labor Team, Galenica confirms its previous 2025 outlook for consolidated net sales with growth of between 3% and 5% and an increase in EBIT¹ of between 7% and 9%.

Galenica continues to plan to pay a dividend at least at the previous year’s level.

Net sales of the Galenica Group January – September 2025
 

“Products & Care” segment

Net sales in the “Products & Care” segment amounted to CHF 1,304.4 million to September 2025, equivalent to an increase of 5.0% over the previous year.

“Retail” business area (B2C)

The “Local Pharmacies” sector (excluding Coop Vitality) increased sales by 5.1% to CHF 1,039.2 million. The expansion effect on growth was 1.7%; the pharmacy network was expanded by five pharmacies net. Adjusted for this effect the sector grew organically by 3.4%, roughly in line with market growth when taking into account the product mix. As in previous months, sales of prescription medications contributed to the growth, not least due to persistently high demand for GLP-1-based³ weight loss products. Sales of dietary supplements contributed to growth too.

Demand for healthcare services in pharmacies also saw positive growth. Over 230,000 fee-based healthcare and consultation services were provided in the first nine months – an increase of 17% on the previous year⁴. The generic substitution rate at Galenica pharmacies remained high at 77.7% at the end of September 2025 (December 2024: 79.2%).

The “Pharmacies at Home” sector achieved sales growth of 1.3% to CHF 58.0 million. The negative growth effect of service adjustments was offset by strong growth of the Amavita and Sun Store online shops.

By way of comparison, drug sales from bricks-and-mortar pharmacies in Switzerland (prescription-only [Rx] and OTC products) grew 5.4%² in the period under review, while the non-drugs segment of the consumer healthcare market contracted by -0.6% in the same period⁵.

“Professionals” business area (B2B)

Consumer healthcare market remains competitive. Galenica’s leading position in the Swiss market was further consolidated with sales growth of 4.6% to CHF 113.8 million. Sales growth is also being boosted by Cooper Consumer Health products, for which Verfora assumed sales responsibility at the start of the year.

Sales growth in Switzerland and the export business were negatively impacted by exceptionally high sales in the prior-year period. As a result, Verfora’s export business declined by -14.6%. By way of comparison, the consumer healthcare market contracted by -0.4%⁵ year on year.

The “Services for Professionals” business (+15.9%) grew significantly, in particular thanks to the inclusion of the Labor Team Group. Without the inclusion of Labor Team the business would have grown by 3.2%, with Lifestage Solutions and Medifilm once again driving growth with care homes and home care organisations.

“Logistics & IT” segment

The “Logistics & IT” segment generated net sales of CHF 2,479.9 million (+5.0%) in the first nine months of the 2025 financial year. This segment comprises Galenica’s logistics and IT platforms and offers services to healthcare providers.

“Wholesale” sector

The “Wholesale” sector generated net sales of CHF 2,375.4 million (+5.0%). Growth in the pharmacy business amounted to 5.4%, while growth of 4.4% was achieved in the wholesale business with physicians. This slightly outperformed market growth. By way of comparison, the overall pharmaceutical market grew by 5.1%² in the reporting period; the physicians segment generated growth of 4.2%², and the bricks-and-mortar pharmacy segment grew by 5.4%². Overall market growth was supported by hospitals and mail-order pharmacies that are not core customers in the wholesale business.

“Logistics & IT Services” sector

The “Logistics & IT Services” sector performed as expected with growth of 6.4%, driven in particular by an increase in internal IT services. HCI Solutions also performed well, registering 375 million CDS Checks (+42%) on the Documedis® platform since the start of the year.

____________________________

1 Excluding the effects of IFRS 16 and IAS 19.

2 IQVIA, Pharmaceutical Market Switzerland, YTD September 2025.

3 GLP-1 stands for glucagon-like peptide 1, a hormone produced in the intestine, and plays an important role in regulating blood sugar levels.

4 New calculation methodology covering all advisory services, including vaccinations and other services such as preventive health checks. The previous year’s figure was also adjusted.

5 IQVIA, Consumer Health Market Switzerland, YTD September 2025.

Upcoming dates

For further information, please contact:

Welcome to the Galenica network!
Around 8,000 employees at Galenica work tirelessly to improve the health and well-being of the people of Switzerland every day. With its pharmacies, pharmaceutical logistics providers, products, services and home care, Galenica has a broad and successful position in the market. We are shaping the future of healthcare in collaboration with our strong partners – by drawing on the diverse skills and extensive expertise of our entire network. Our ambition is to fulfil the needs of customers and patients in the Swiss healthcare market seamlessly, efficiently and personally.

Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Additional information about Galenica can be found at www.galenica.com.